BeneVir Biopharm, Inc.

In the emerging field of oncolytic virotherapy, BeneVir is developing an improved therapeutic platform that can be adapted to target a wide variety of cancers. The company is working with leaders in the field to create a pipeline of next generation immunotherapies that will have a significant impact on the fight against cancer.